CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
LY900014 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02525744
NCT02525744Phase 1Completed
CompareCT.gov

Pharmacokinetics, Glucodynamics, Safety, and Tolerability of a Novel LY900014 Formulation

Eli Lilly and Company·interventional·Posted Aug 17, 2015·Updated May 19, 2020

In Brief

A Phase 1 clinical trial evaluating LY900014 and Insulin Lispro (Humalog) for Healthy. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This study evaluates a new formulation of LY900014, a drug that lowers blood sugar. It is administered by injection under the skin of the abdomen. The study will be conducted in healthy people to investigate how quickly and how much LY900014 is absorbed and the effect of different doses of LY900014 on blood sugar levels. Side effects and tolerability will be documented. The study will last for about 8 to 9 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 17, 2015
Enrollment StartAug 1, 2015
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.9 years ago

Interventions

LY900014drug

Administered SC

Insulin Lispro (Humalog)drug

Administered SC